CymaBay Therapeutics Inc (NASDAQ:CBAY) reached a new 52-week low on Tuesday after BidaskClub downgraded the stock from a hold rating to a sell rating. The stock traded as low as $4.82 and last traded at $5.38, with a volume of 5745570 shares. The stock had previously closed at $11.09.
Several other equities research analysts also recently weighed in on CBAY. Oppenheimer set a $18.00 target price on shares of CymaBay Therapeutics and gave the stock a “buy” rating in a research report on Friday, February 15th. Piper Jaffray Companies set a $30.00 price target on shares of CymaBay Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 20th. Roth Capital reaffirmed a “buy” rating on shares of CymaBay Therapeutics in a report on Tuesday, February 19th. Leerink Swann started coverage on shares of CymaBay Therapeutics in a report on Friday, February 22nd. They issued an “outperform” rating and a $22.00 price target for the company. Finally, Svb Leerink reaffirmed an “outperform” rating on shares of CymaBay Therapeutics in a report on Thursday, February 21st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $15.44.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of CymaBay Therapeutics by 16.3% in the 4th quarter. BlackRock Inc. now owns 5,161,581 shares of the biopharmaceutical company’s stock valued at $40,622,000 after buying an additional 722,753 shares during the period. Perceptive Advisors LLC boosted its holdings in shares of CymaBay Therapeutics by 71.1% in the 1st quarter. Perceptive Advisors LLC now owns 4,212,821 shares of the biopharmaceutical company’s stock valued at $55,946,000 after buying an additional 1,750,000 shares during the period. Eagle Asset Management Inc. boosted its holdings in shares of CymaBay Therapeutics by 5.6% in the 1st quarter. Eagle Asset Management Inc. now owns 3,011,623 shares of the biopharmaceutical company’s stock valued at $39,994,000 after buying an additional 158,650 shares during the period. Vanguard Group Inc. boosted its stake in CymaBay Therapeutics by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 2,789,188 shares of the biopharmaceutical company’s stock valued at $30,903,000 after purchasing an additional 109,989 shares during the period. Finally, Foresite Capital Management IV LLC boosted its stake in CymaBay Therapeutics by 30.0% during the 4th quarter. Foresite Capital Management IV LLC now owns 2,631,258 shares of the biopharmaceutical company’s stock valued at $20,708,000 after purchasing an additional 607,889 shares during the period. 99.53% of the stock is owned by institutional investors and hedge funds.
CymaBay Therapeutics (NASDAQ:CBAY) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). As a group, research analysts forecast that CymaBay Therapeutics Inc will post -1.48 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://sportsperspectives.com/2019/06/13/cymabay-therapeutics-nasdaqcbay-hits-new-12-month-low-on-analyst-downgrade.html.
CymaBay Therapeutics Company Profile (NASDAQ:CBAY)
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Read More: Call Option
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.